IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies for the treatment of cancer using personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL). Its lead product, Amtagvi, has been approved in the US and Canada for the treatment of second line metastatic melanoma after progression on checkpoint therapies.